Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20633036rdf:typepubmed:Citationlld:pubmed
pubmed-article:20633036lifeskim:mentionsumls-concept:C0011923lld:lifeskim
pubmed-article:20633036lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:20633036lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:20633036lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:20633036lifeskim:mentionsumls-concept:C0019564lld:lifeskim
pubmed-article:20633036lifeskim:mentionsumls-concept:C0014556lld:lifeskim
pubmed-article:20633036lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:20633036pubmed:issue9lld:pubmed
pubmed-article:20633036pubmed:dateCreated2010-9-13lld:pubmed
pubmed-article:20633036pubmed:abstractTextBased on experimental findings, overexpression of P-glycoprotein at the blood-brain barrier has been suggested to be a contributor to pharmacoresistance of the epileptic brain. We test a technique for evaluation of interindividual differences of elevated transporter function, through microPET analysis of the impact of the P-glycoprotein modulator tariquidar. The preclinical study is intended for eventual translation to clinical research of patients with pharmacoresistant seizure disorders.lld:pubmed
pubmed-article:20633036pubmed:languageenglld:pubmed
pubmed-article:20633036pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20633036pubmed:citationSubsetIMlld:pubmed
pubmed-article:20633036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20633036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20633036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20633036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20633036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20633036pubmed:statusMEDLINElld:pubmed
pubmed-article:20633036pubmed:monthSeplld:pubmed
pubmed-article:20633036pubmed:issn1528-1167lld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:PotschkaHeidr...lld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:BartensteinPe...lld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:CummingPaulPlld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:WinterPetraPlld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:XiongGuomingGlld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:la...lld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:WänglerBjörnBlld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:BöningGuidoGlld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:PekcecAntonAlld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:FuestChristin...lld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:SoerensenJonn...lld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:SchlichtigerJ...lld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:BartmannHeroHlld:pubmed
pubmed-article:20633036pubmed:authorpubmed-author:JustTheresaTlld:pubmed
pubmed-article:20633036pubmed:copyrightInfoWiley Periodicals, Inc. © 2010 International League Against Epilepsy.lld:pubmed
pubmed-article:20633036pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20633036pubmed:volume51lld:pubmed
pubmed-article:20633036pubmed:ownerNLMlld:pubmed
pubmed-article:20633036pubmed:authorsCompleteYlld:pubmed
pubmed-article:20633036pubmed:pagination1780-90lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:meshHeadingpubmed-meshheading:20633036...lld:pubmed
pubmed-article:20633036pubmed:year2010lld:pubmed
pubmed-article:20633036pubmed:articleTitleImaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy.lld:pubmed
pubmed-article:20633036pubmed:affiliationInstitute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University, Munich, Germany.lld:pubmed
pubmed-article:20633036pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20633036pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20633036lld:pubmed